Overview

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Status:
Completed
Trial end date:
2017-02-07
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America. The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses and multiple doses of NNC0165-1562 in overweight to obese but otherwise healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S